
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (... 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.515 | -11.3938053097 | 4.52 | 4.865 | 3.92 | 687335 | 4.49600351 | CS |
4 | -1.865 | -31.7717206133 | 5.87 | 6.91 | 3.92 | 963249 | 5.18204744 | CS |
12 | -3.195 | -44.375 | 7.2 | 7.33 | 3.92 | 950717 | 5.55851075 | CS |
26 | -10.715 | -72.7921195652 | 14.72 | 17.41 | 3.92 | 907326 | 7.95246144 | CS |
52 | -25.655 | -86.4969656102 | 29.66 | 36.25 | 3.92 | 815399 | 14.54663113 | CS |
156 | -9.355 | -70.0224550898 | 13.36 | 36.25 | 3.92 | 576214 | 16.70283638 | CS |
260 | -35.995 | -89.9875 | 40 | 55.11 | 3.92 | 466565 | 18.20909925 | CS |
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관